Answer
Delstrigo is indicated for adolescents aged at least 12 years, weighing at least 35 kg, with HIV-1, no past or present evidence of resistance to the NNRTI class, lamivudine or tenofovir, and toxicities precluding other regimens that do not contain tenofovir disoproxil.
Sources for this answer
- Delstrigo 100 mg /300 mg /245 mg film-coated tabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.1 Therapeutic Indications · Version 16Document updated
Sources checked